In a nutshell
This study looked at the effect of chemoradiation (CRT) and local surgical treatment (local excision – LE) on quality of life in patients with stage II rectal cancer. It found that this treatment had little effect on lower bowel function (anorectum) and quality of life.
Some background
Anorectal cancer is often treated with total mesorectal excision (TME, removal of the tumor and surrounding tissue) which can significantly affect function and quality of life of patients. Chemoradiation to shrink the tumor followed by surgical removal may help to save function and quality of life (QoL). It is necessary to assess the effect that this treatment has on anorectal function (AF) and QoL.
Methods & findings
The study assessed 71 patients who underwent CRT + LE treatment for stage II rectal cancer. Patients were treated with the chemotherapies oxaliplatin (Eloxatin) and capecitabine (Xeloda) and radiation, followed by LE. Factors such as control of bowel movements and general lifestyle were examined. Patients were assessed for QoL and AF before treatment and 12 months after CRT+LE treatment.
There was no significant decrease in AF compared to normal. Some patients reported a reduced QoL related to their bowel control.
The bottom line
This study concluded that stage II rectal cancer patients treated with CRT+LE do not experience worse bowel function or quality of life overall, compared to before treatment.
The fine print
This study is limited by the small number of patients and the short time of follow-up.
What’s next?
Talk to your doctor about the possible benefits and risks of chemoradiation with local surgical treatment.
Published By :
Diseases of the colon and rectum
Date :
May 01, 2017
